Product

Floximed

2 forms: eye drops, ointment. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form	Dose	Frequency	Georgia
3 mg/g (0.3%), Ointment	No label dose in the reference yet	-	Georgia Yes, human In force until 03 Feb 2027 Human (Ministry of Health, RAMA) In the register: Floximed 0.3% eye ointment 5 g № რ-034300 Georgia Ministry exact human-product register Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration Floximed 3 mg/g (0.3%), Ointment eye ointment 5 g, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Veterinarian-directed ointment treatment of selected superficial susceptible bacterial ocular infection when prolonged surface contact is useful and corneal structural integrity permits safe application 4.8/10 Weak evidence support vetman assessment Floximed 3 mg/g (0.3%), eye ointment 5 g, human medicine Assessed clinical scopeDog · Veterinarian-directed ointment treatment of selected superficial susceptible bacterial ocular infection when prolonged surface contact is useful and corneal structural integrity permits safe application · Into the eye Care settingVeterinarian-directed clinic/home treatment after complete ocular examination, with early recheck and cytology/culture for deep, melting, recurrent, severe or nonresponsive disease. vetman score 4.8/10 Weak evidence support Evidence confidence: Low Georgia: Yes, human · № რ-034300 · Verified on 22 Oct 2026 Off-label use A potentially useful retained-contact form for selected superficial susceptible infection, but direct veterinary ointment evidence is thin and it should not be used through a dangerously compromised cornea. Regulatory and scientific credibility4.0/10 Exact strength, form, pack and current Georgian human registration are traceable, but no complete current Floximed regulator label or exact-product veterinary dossier was found; EU/GB/US status remains unknown. Because efficacy evidence is formulation-mismatched, the PLAYBOOK gate caps scientific credibility at 4.0. Clinical efficacy3.5/10 The active can treat susceptible superficial infection, but ointment comparator evidence is human conjunctivitis-focused and does not establish Floximed canine keratitis outcomes, intensive-ulcer exposure or superiority over solution/other agents. Safety and tolerability6.0/10 Topical systemic exposure is expected to be low, but exact Floximed excipients and target-animal safety are undocumented; irritation, blur, keratopathy, contamination, hypersensitivity and tube-tip trauma or intraocular ointment entry are clinically important. Clinical practicality6.5/10 Ointment can prolong surface contact and reduce administration frequency in selected superficial disease, but causes temporary blur, must be applied last and is unsuitable when contact trauma or passage through a compromised cornea is plausible. Full-course cost-effectiveness- No verified current Georgian patient-adjusted full-course price is available, so cost is excluded. Important safety and use flags Human ophthalmic medicine used off-label in dogs and cats. The exact Georgian human registration does not establish veterinary authorisation, animal efficacy or a product-specific animal dose. Do not treat an undifferentiated red or painful eye empirically. Perform complete ocular examination, fluorescein staining and tear-film/ocular-surface assessment; identify trauma, foreign body, dry eye, uveitis, glaucoma, viral, fungal or immune-mediated disease. Obtain cytology and culture/susceptibility for deep, stromal, melting, rapidly progressive, recurrent, previously treated or nonresponsive keratitis, preferably before the first dose when this will not dangerously delay treatment. Ciprofloxacin is strong against many Pseudomonas isolates but does not reliably cover Streptococcus or every ocular isolate. Do not assume class-wide or regional susceptibility; combine, narrow or change treatment from findings and response. No exact Floximed dog/cat regimen is established. Do not transfer the 25–50 mg/kg oral ciprofloxacin dose, a human comparator schedule, another fluoroquinolone schedule or solution frequency to ointment. Apply ointment after all other topical eye medicines and avoid use where tube-tip trauma or passage through a melting, perforated, freshly operated or structurally weak cornea is plausible. Never inject into the eye. Use one container for one patient, preserve tip sterility, close promptly and follow the exact pack discard/storage instruction; these Floximed in-use details were not independently verified. Monitor pain, blepharospasm, discharge, hyperaemia, corneal opacity, staining, crystalline deposit, epitheliopathy, irritation, allergy and vision. Worsening, melting, perforation or vision change needs urgent ophthalmic reassessment. Reassess early and document an objective response. De-escalate, narrow, combine, change or stop according to culture, susceptibility, epithelial healing and diagnosis; do not extend fluoroquinolone exposure solely because redness persists. Exact safety in puppies/kittens, pregnancy, lactation, breeding animals, severe dry eye and prolonged or repeated courses is not established. Low systemic exposure from comparator products is not proof of exact Floximed safety. Assessment sources Uzbekistan Floximed ointment2011 Floximed GE register2026 Ciloxan ointment label2024 MSD ophthalmic antimicrobials2026 Canine keratitis Australia2016 Canine ulcer isolates US2020 WSAVA eye stewardship2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Veterinarian-directed ointment treatment of selected superficial susceptible bacterial ocular infection when prolonged surface contact is useful and corneal structural integrity permits safe application 4.7/10 Weak evidence support vetman assessment Floximed 3 mg/g (0.3%), eye ointment 5 g, human medicine Assessed clinical scopeCat · Veterinarian-directed ointment treatment of selected superficial susceptible bacterial ocular infection when prolonged surface contact is useful and corneal structural integrity permits safe application · Into the eye Care settingVeterinarian-directed clinic/home treatment after complete ocular examination, with early recheck and cytology/culture for deep, melting, recurrent, severe or nonresponsive disease. vetman score 4.7/10 Weak evidence support Evidence confidence: Low Georgia: Yes, human · № რ-034300 · Verified on 22 Oct 2026 Off-label use A potentially useful retained-contact form for selected superficial susceptible infection, but direct veterinary ointment evidence is thin and it should not be used through a dangerously compromised cornea. Regulatory and scientific credibility4.0/10 Exact strength, form, pack and current Georgian human registration are traceable, but no complete current Floximed regulator label or exact-product veterinary dossier was found; EU/GB/US status remains unknown. Because efficacy evidence is formulation-mismatched, the PLAYBOOK gate caps scientific credibility at 4.0. Clinical efficacy3.0/10 Ciprofloxacin has useful feline isolate activity, but the ointment form lacks direct feline outcome or PK evidence and should not be extrapolated to deep, melting or mixed-pathogen disease from solution susceptibility alone. Safety and tolerability6.0/10 Topical systemic exposure is expected to be low, but exact Floximed excipients and target-animal safety are undocumented; irritation, blur, keratopathy, contamination, hypersensitivity and tube-tip trauma or intraocular ointment entry are clinically important. Clinical practicality6.5/10 Ointment can prolong surface contact and reduce administration frequency in selected superficial disease, but causes temporary blur, must be applied last and is unsuitable when contact trauma or passage through a compromised cornea is plausible. Full-course cost-effectiveness- No verified current Georgian patient-adjusted full-course price is available, so cost is excluded. Important safety and use flags Human ophthalmic medicine used off-label in dogs and cats. The exact Georgian human registration does not establish veterinary authorisation, animal efficacy or a product-specific animal dose. Do not treat an undifferentiated red or painful eye empirically. Perform complete ocular examination, fluorescein staining and tear-film/ocular-surface assessment; identify trauma, foreign body, dry eye, uveitis, glaucoma, viral, fungal or immune-mediated disease. Obtain cytology and culture/susceptibility for deep, stromal, melting, rapidly progressive, recurrent, previously treated or nonresponsive keratitis, preferably before the first dose when this will not dangerously delay treatment. Ciprofloxacin is strong against many Pseudomonas isolates but does not reliably cover Streptococcus or every ocular isolate. Do not assume class-wide or regional susceptibility; combine, narrow or change treatment from findings and response. No exact Floximed dog/cat regimen is established. Do not transfer the 25–50 mg/kg oral ciprofloxacin dose, a human comparator schedule, another fluoroquinolone schedule or solution frequency to ointment. Apply ointment after all other topical eye medicines and avoid use where tube-tip trauma or passage through a melting, perforated, freshly operated or structurally weak cornea is plausible. Never inject into the eye. Use one container for one patient, preserve tip sterility, close promptly and follow the exact pack discard/storage instruction; these Floximed in-use details were not independently verified. Monitor pain, blepharospasm, discharge, hyperaemia, corneal opacity, staining, crystalline deposit, epitheliopathy, irritation, allergy and vision. Worsening, melting, perforation or vision change needs urgent ophthalmic reassessment. Reassess early and document an objective response. De-escalate, narrow, combine, change or stop according to culture, susceptibility, epithelial healing and diagnosis; do not extend fluoroquinolone exposure solely because redness persists. Exact safety in puppies/kittens, pregnancy, lactation, breeding animals, severe dry eye and prolonged or repeated courses is not established. Low systemic exposure from comparator products is not proof of exact Floximed safety. Assessment sources Uzbekistan Floximed ointment2011 Floximed GE register2026 Ciloxan ointment label2024 MSD ophthalmic antimicrobials2026 Feline bacterial keratitis study2020 WSAVA eye stewardship2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Ciprofloxacin3 mg/g Formulation Type Ointment Administration route Into the eye Manufacturer EIPICO · Egypt Registration Georgia Yes, human In force until 03 Feb 2027 Human (Ministry of Health, RAMA) In the register: Floximed 0.3% eye ointment 5 g № რ-034300 Georgia Ministry exact human-product register Verified on: 22 Oct 2026 EU Not confirmed EU/EEA exact-product status not established Verified on: 23 Oct 2026 UK Not confirmed GB exact-product status not established Verified on: 23 Oct 2026 US Not confirmed US exact-product status not established Verified on: 23 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026 Information not fully verified No product-specific veterinary dose is established. Do not transfer the oral 25–50 mg/kg ciprofloxacin dose or a human comparator schedule. Select frequency and duration from diagnosis, depth/severity, cytology/culture, susceptibility, response and ophthalmic review.
3 mg/ml (0.3%), Eye drops	No label dose in the reference yet	-	Georgia Yes, human In force until 09 Feb 2028 Human (Ministry of Health, RAMA) In the register: Floximed 0.3% eye drops 5 ml № რ-037297 Georgia Ministry exact human-product register Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration Floximed 3 mg/ml (0.3%), Eye drops eye drops 5 ml, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Veterinarian-directed topical treatment of a diagnosed susceptible bacterial ocular-surface infection, including selected infected keratitis; culture-led for complicated disease 4.9/10 Weak evidence support vetman assessment Floximed 3 mg/ml (0.3%), eye drops 5 ml, human medicine Assessed clinical scopeDog · Veterinarian-directed topical treatment of a diagnosed susceptible bacterial ocular-surface infection, including selected infected keratitis; culture-led for complicated disease · Into the eye Care settingVeterinarian-directed clinic/home treatment after complete ocular examination, with early recheck and cytology/culture for deep, melting, recurrent, severe or nonresponsive disease. vetman score 4.9/10 Weak evidence support Evidence confidence: Low Georgia: Yes, human · № რ-037297 · Verified on 22 Oct 2026 Off-label use Useful culture-aware topical fluoroquinolone activity, strongest for susceptible Gram-negative infection, but incomplete exact-product documentation and variable streptococcal/overall coverage prevent routine monotherapy claims. Regulatory and scientific credibility4.0/10 Exact strength, form, pack and current Georgian human registration are traceable, but no complete current Floximed regulator label or exact-product veterinary dossier was found; EU/GB/US status remains unknown. Because efficacy evidence is formulation-mismatched, the PLAYBOOK gate caps scientific credibility at 4.0. Clinical efficacy4.0/10 Canine isolate and ocular-PK studies support useful Gram-negative, especially Pseudomonas, activity, but only 69% overall susceptibility in one large cohort, poor Streptococcus coverage, regional variation and absent exact-product outcomes make monotherapy situational. Safety and tolerability6.5/10 Topical comparator exposure is low and immature-dog ocular study found no articular lesions, but Floximed excipients, sterility/in-use limits and dog/cat safety are incompletely documented; irritation, deposits, keratopathy, contamination and hypersensitivity remain relevant. Clinical practicality5.5/10 Drops avoid tube contact and allow intensive treatment, but severe keratitis may require dosing every one to few hours, multiple agents, culture and frequent rechecks; no exact Floximed animal schedule or calibrated drop volume is established. Full-course cost-effectiveness- No verified current Georgian patient-adjusted full-course price is available, so cost is excluded. Important safety and use flags Human ophthalmic medicine used off-label in dogs and cats. The exact Georgian human registration does not establish veterinary authorisation, animal efficacy or a product-specific animal dose. Do not treat an undifferentiated red or painful eye empirically. Perform complete ocular examination, fluorescein staining and tear-film/ocular-surface assessment; identify trauma, foreign body, dry eye, uveitis, glaucoma, viral, fungal or immune-mediated disease. Obtain cytology and culture/susceptibility for deep, stromal, melting, rapidly progressive, recurrent, previously treated or nonresponsive keratitis, preferably before the first dose when this will not dangerously delay treatment. Ciprofloxacin is strong against many Pseudomonas isolates but does not reliably cover Streptococcus or every ocular isolate. Do not assume class-wide or regional susceptibility; combine, narrow or change treatment from findings and response. No exact Floximed dog/cat regimen is established. Do not transfer the 25–50 mg/kg oral ciprofloxacin dose, a human comparator schedule, another fluoroquinolone schedule or solution frequency to ointment. Keep topical eye medicines at least five minutes apart; if ointment is also prescribed, use it last. Do not let the dropper tip touch eye, eyelid, hair, fingers or another surface. Never inject into the eye. Use one container for one patient, preserve tip sterility, close promptly and follow the exact pack discard/storage instruction; these Floximed in-use details were not independently verified. Monitor pain, blepharospasm, discharge, hyperaemia, corneal opacity, staining, crystalline deposit, epitheliopathy, irritation, allergy and vision. Worsening, melting, perforation or vision change needs urgent ophthalmic reassessment. Reassess early and document an objective response. De-escalate, narrow, combine, change or stop according to culture, susceptibility, epithelial healing and diagnosis; do not extend fluoroquinolone exposure solely because redness persists. Exact safety in puppies/kittens, pregnancy, lactation, breeding animals, severe dry eye and prolonged or repeated courses is not established. Low systemic exposure from comparator products is not proof of exact Floximed safety. Assessment sources EIPICO Floximed drops2026 Floximed GE register2026 Ciprofloxacin drops label2026 MSD ophthalmic antimicrobials2026 Canine keratitis Australia2016 Canine ulcer isolates US2020 Canine ocular ciprofloxacin PK2005 WSAVA eye stewardship2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Veterinarian-directed topical treatment of a diagnosed susceptible bacterial ocular-surface infection, including selected infected keratitis; culture-led for complicated disease 4.9/10 Weak evidence support vetman assessment Floximed 3 mg/ml (0.3%), eye drops 5 ml, human medicine Assessed clinical scopeCat · Veterinarian-directed topical treatment of a diagnosed susceptible bacterial ocular-surface infection, including selected infected keratitis; culture-led for complicated disease · Into the eye Care settingVeterinarian-directed clinic/home treatment after complete ocular examination, with early recheck and cytology/culture for deep, melting, recurrent, severe or nonresponsive disease. vetman score 4.9/10 Weak evidence support Evidence confidence: Low Georgia: Yes, human · № რ-037297 · Verified on 22 Oct 2026 Off-label use Useful culture-aware topical fluoroquinolone activity, strongest for susceptible Gram-negative infection, but incomplete exact-product documentation and variable streptococcal/overall coverage prevent routine monotherapy claims. Regulatory and scientific credibility4.0/10 Exact strength, form, pack and current Georgian human registration are traceable, but no complete current Floximed regulator label or exact-product veterinary dossier was found; EU/GB/US status remains unknown. Because efficacy evidence is formulation-mismatched, the PLAYBOOK gate caps scientific credibility at 4.0. Clinical efficacy4.0/10 A feline referral cohort found 94% ciprofloxacin susceptibility and supports it among initial keratitis options, but evidence is retrospective and in-vitro, regional resistance matters and no exact-product feline outcome trial exists. Safety and tolerability6.5/10 Topical comparator exposure is low and immature-dog ocular study found no articular lesions, but Floximed excipients, sterility/in-use limits and dog/cat safety are incompletely documented; irritation, deposits, keratopathy, contamination and hypersensitivity remain relevant. Clinical practicality5.5/10 Drops avoid tube contact and allow intensive treatment, but severe keratitis may require dosing every one to few hours, multiple agents, culture and frequent rechecks; no exact Floximed animal schedule or calibrated drop volume is established. Full-course cost-effectiveness- No verified current Georgian patient-adjusted full-course price is available, so cost is excluded. Important safety and use flags Human ophthalmic medicine used off-label in dogs and cats. The exact Georgian human registration does not establish veterinary authorisation, animal efficacy or a product-specific animal dose. Do not treat an undifferentiated red or painful eye empirically. Perform complete ocular examination, fluorescein staining and tear-film/ocular-surface assessment; identify trauma, foreign body, dry eye, uveitis, glaucoma, viral, fungal or immune-mediated disease. Obtain cytology and culture/susceptibility for deep, stromal, melting, rapidly progressive, recurrent, previously treated or nonresponsive keratitis, preferably before the first dose when this will not dangerously delay treatment. Ciprofloxacin is strong against many Pseudomonas isolates but does not reliably cover Streptococcus or every ocular isolate. Do not assume class-wide or regional susceptibility; combine, narrow or change treatment from findings and response. No exact Floximed dog/cat regimen is established. Do not transfer the 25–50 mg/kg oral ciprofloxacin dose, a human comparator schedule, another fluoroquinolone schedule or solution frequency to ointment. Keep topical eye medicines at least five minutes apart; if ointment is also prescribed, use it last. Do not let the dropper tip touch eye, eyelid, hair, fingers or another surface. Never inject into the eye. Use one container for one patient, preserve tip sterility, close promptly and follow the exact pack discard/storage instruction; these Floximed in-use details were not independently verified. Monitor pain, blepharospasm, discharge, hyperaemia, corneal opacity, staining, crystalline deposit, epitheliopathy, irritation, allergy and vision. Worsening, melting, perforation or vision change needs urgent ophthalmic reassessment. Reassess early and document an objective response. De-escalate, narrow, combine, change or stop according to culture, susceptibility, epithelial healing and diagnosis; do not extend fluoroquinolone exposure solely because redness persists. Exact safety in puppies/kittens, pregnancy, lactation, breeding animals, severe dry eye and prolonged or repeated courses is not established. Low systemic exposure from comparator products is not proof of exact Floximed safety. Assessment sources EIPICO Floximed drops2026 Floximed GE register2026 Ciprofloxacin drops label2026 MSD ophthalmic antimicrobials2026 Feline bacterial keratitis study2020 WSAVA eye stewardship2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Ciprofloxacin3 mg/ml Formulation Type Eye drops Administration route Into the eye Manufacturer EIPICO · Egypt Registration Georgia Yes, human In force until 09 Feb 2028 Human (Ministry of Health, RAMA) In the register: Floximed 0.3% eye drops 5 ml № რ-037297 Georgia Ministry exact human-product register Verified on: 22 Oct 2026 EU Not confirmed EU/EEA exact-product status not established Verified on: 23 Oct 2026 UK Not confirmed GB exact-product status not established Verified on: 23 Oct 2026 US Not confirmed US exact-product status not established Verified on: 23 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026 Information not fully verified No product-specific veterinary dose is established. Do not transfer the oral 25–50 mg/kg ciprofloxacin dose or a human comparator schedule. Select frequency and duration from diagnosis, depth/severity, cytology/culture, susceptibility, response and ophthalmic review.

Ciprofloxacin: No dose supported by a publicly verifiable source yet

Known Contraindications

Critical
Do not use ciprofloxacin in patients with known hypersensitivity to ciprofloxacin or another fluoroquinolone.
Warning
Both ciprofloxacin and moxifloxacin have been associated with potentially fatal antimicrobial-induced colitis.

Sources: MSD Vet Manual
Warning
Avoid excessive or prolonged quinolone use in immature animals because cartilage erosion and permanent lameness have occurred in growing dogs and foals.

Sources: MSD Vet Manual
Warning (Cat)
Not well absorbed in cats

Sources: MSD Vet Manual

Known Drug Interactions

Major warning Ciprofloxacin + Aminophylline
Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)

Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce the aminophylline dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.

Sources: FDA
Major warning Theophylline + Ciprofloxacin
Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)

Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce its dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.

Sources: FDA

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Floximed

Forms and doses2 of 2 in force in Georgia

Floximed 3 mg/g (0.3%), Ointment

Floximed 3 mg/ml (0.3%), Eye drops

Known Contraindications

Known Drug Interactions

Related products

Same therapeutic group 59

All of this shows in vetman as you prescribe